IR@PKUHSC  > 北京大学第一临床医学院  > 感染疾病科
学科主题临床医学
Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon
Hou, Feng-Qin1; Song, Liu-Wei2; Yuan, Quan2; Fang, Lin-Lin2; Ge, Sheng-Xiang2; Zhang, Jun2; Sheng, Ji-Fang3; Xie, Dong-Ying4; Shang, Jia5; Wu, Shu-Huan6; Sun, Yong-Tao7; Wei, Shao-Feng8; Wang, Mao-Rong9; Wan, Mo-Bin10; Jia, Ji-Dong11; Luo, Guang-Han12; Tang, Hong13; Li, Shu-Chen14; Niu, Jun-Qi15; Zhou, Wei-dong16; Sun, Li16; Xia, Ning-Shao2; Wang, Gui-Qiang1
关键词Quantitative Anti-hbc Chronic Hepatitis b Peg-ifn Treatment Treatment Response Prediction Pretreatment Biomarker
刊名THERANOSTICS
2015
DOI10.7150/thno.10636
5期:3页:218-226
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental
研究领域[WOS]Research & Experimental Medicine
关键词[WOS]VIRUS INFECTION ; ANTIGEN ; LAMIVUDINE ; THERAPY ; SEROCONVERSION ; COMBINATION
英文摘要

A recent study revealed that quantitative hepatitis B core antibody (qAnti-HBc) level could serve as a novel marker for predicting treatment response. In the present study, we further investigated the predictive value of qAnti-HBc level in HBeAg-positive patients undergoing PEG-IFN therapy. A total of 140 HBeAg-positive patients who underwent PEG-IFN therapy for 48 weeks and follow-up for 24 weeks were enrolled in this study. Serum samples were taken every 12 weeks post-treatment. The predictive value of the baseline qAnti-HBc level for treatment response was evaluated. Patients were further divided into 2 groups according to the baseline qAnti-HBc level, and the response rate was compared. Additionally, the kinetics of the virological and biochemical parameters were analyzed. Patients who achieved response had a significantly higher baseline qAnti-HBc level (serological response [SR], 4.52 +/- 0.36 vs. 4.19 +/- 0.58, p=0.001; virological response [VR], 4.53 +/- 0.35 vs. 4.22 +/- 0.57, p=0.005; combined response [CR], 4.50 +/- 0.36 vs. 4.22 +/- 0.58, p=0.009)). Baseline qAnti-HBc was the only parameter that was independently correlated with SR (p=0.008), VR (p=0.010) and CR(p=0.019). Patients with baseline qAnti-HBc levels >= 30,000 IU/mL had significantly higher response rates, more HBV DNA suppression, and better hepatitis control in PEG-IFN treatment. In conclusion, qAnti-HBc level may be a novel biomarker for predicting treatment response in HBeAg-positive patients receiving PEG-IFN therapy.

语种英语
WOS记录号WOS:000345207600001
项目编号30925030 ; 81371819 ; 2012ZX10002005 ; 2011ZX09101-008-06 ; 2012ZX10002006 ; 2013ZX10002005 ; D121100003912002
资助机构National Science Fund ; Technological Major Project ; Beijing Scientific &amp ; Technological Project
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/52449
专题北京大学第一临床医学院_感染疾病科
作者单位1.Henan Prov Peoples Hosp, Dept Infect Dis, Zhengzhou, Peoples R China
2.PLA 81st Hosp, Dept Infect Dis, Nanjing, Jiangsu, Peoples R China
3.Peking Univ, Hosp 1, Ctr Liver Dis, Dept Infect Dis, Beijing 100871, Peoples R China
4.Xiamen Univ, Sch Publ Hlth, Natl Inst Diagnost & Vaccine Dev Infect Dis, State Key Lab Mol Vaccinol & Mol Diagnost, Xiamen, Peoples R China
5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China
6.Sun Yat Sen Univ, Affiliated Hosp 3, Dept Infect Dis, Guangzhou 510275, Guangdong, Peoples R China
7.Zhengzhou Univ, Affiliated Hosp 1, Dept Infect Dis, Zhengzhou 450052, Peoples R China
8.Fourth Mil Med Univ, Tang Du Hosp, Dept Infect Dis, Xian 710032, Peoples R China
9.Anhui Med Univ, Affiliated Hosp 1, Dept Infect Dis, Hefei, Peoples R China
10.Second Mil Med Univ, Changhai Hosp, Dept Infect Dis, Shanghai, Peoples R China
11.Capital Med Univ, Beijing Friendship Hosp, Liver Res Ctr, Beijing, Peoples R China
12.Guangxi Med Univ, Affiliated Hosp 1, Dept Infect Dis, Nanning, Peoples R China
13.Sichuan Univ, West China Hosp, Ctr Infect Dis, Chengdu 610064, Peoples R China
14.Harbin Med Univ, Affiliated Hosp 2, Dept Infect Dis, Harbin, Peoples R China
15.Changchun Univ, Affiliated Hosp 1, Ctr Liver Dis, Changchun, Peoples R China
16.Xiamen Amoytop Biotech Co Ltd, Xiamen, Peoples R China
推荐引用方式
GB/T 7714
Hou, Feng-Qin,Song, Liu-Wei,Yuan, Quan,et al. Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon[J]. THERANOSTICS,2015,5(3):218-226.
APA Hou, Feng-Qin.,Song, Liu-Wei.,Yuan, Quan.,Fang, Lin-Lin.,Ge, Sheng-Xiang.,...&Wang, Gui-Qiang.(2015).Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon.THERANOSTICS,5(3),218-226.
MLA Hou, Feng-Qin,et al."Quantitative Hepatitis B Core Antibody Level Is a New Predictor for Treatment Response In HBeAg-positive Chronic Hepatitis B Patients Receiving Peginterferon".THERANOSTICS 5.3(2015):218-226.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hou, Feng-Qin]的文章
[Song, Liu-Wei]的文章
[Yuan, Quan]的文章
百度学术
百度学术中相似的文章
[Hou, Feng-Qin]的文章
[Song, Liu-Wei]的文章
[Yuan, Quan]的文章
必应学术
必应学术中相似的文章
[Hou, Feng-Qin]的文章
[Song, Liu-Wei]的文章
[Yuan, Quan]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。